- Our Story - In Memory Vaccination and Immunotherapy for
Alzheimer’s Disease Vaccination against amyloid is a promising
approach for the development of Alzheimer’s disease (AD)
therapeutics. Approximately half of the investigational new
therapeutics in human clinical trials for AD are active or
passive immunotherapeutics. Active vaccination involves the
injection of an antigen and relies on the production of
antibodies in the vaccinated patient. Four human clinical trials
of active vaccination currently are under way. Passive
immunization is also a promising strategy that involves the
production of antibodies outside of the patient and injection of
these antibodies. There are currently 12 clinical trials of
passive immunization. You can check for Alzheimer therapeutics
in human clinical trials by visiting www.clinicaltrials.gov and
searching for key words “Alzheimer’s and immunotherapy.”
Thinking out of the box The development of vaccinations as a
strategy for treating or preventing Alzheimer’s is an example